| ■ 영문 제목 : Global Female Sexual Dysfunction Treatment Market 2023-2027
|
 | ■ 상품코드 : IRTNTR70409-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2022년 11월
■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (24시간 이내)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1명 열람용) | USD2,500 ⇒환산￦3,375,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산￦5,400,000 | 견적의뢰/주문/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
테크나비오 조사회사는 세계의 여성 성기능 장애 치료 시장 규모가 2022년부터 2027년까지 연평균 34.28% 성장하여, 7760.77백만달러에 달할 것으로 예측하고 있습니다. 본 조사 보고서는 세계의 여성 성기능 장애 치료 시장에 대해 광범위한 조사 및 분석을 실시하여, 개요, 시장 현황, 시장 규모, 과거 시장 규모, 파이브 포스 분석, 연령층별 (40대 이상, 40대 이하) 분석, 제품별 (비호르몬 요법, 호르몬 요법) 분석, 고객 현황, 지역별 현황 (북미, 유럽, 아시아, 미국, 캐나다, 독일, 영국, 프랑스, 기타 지역) 분석, 추진 요인/과제/동향, 기업 현황, 기업 분석 등의 항목을 게재하고 있습니다. 또한 본 조사 자료는 Assos Ilac, Cipla Ltd., Dare Bioscience Inc., Dr Reddys Laboratories Ltd., Duchesnay Inc., Endo International Plc, Freya Pharma Solutions B.V., Lupin Ltd., Mithra Pharmaceuticals SA, Novo Nordisk AS, Palata Technologies Inc., Pfizer Inc., Pharmbio Korea Inc., Sprout Pharmaceuticals Inc., Strategic Science and Technologies LLC 등의 기업 정보가 수록되어 있습니다.
・개요
・시장 현황
・시장 규모
・과거 시장 규모
・파이브 포스 분석
・세계의 여성 성기능 장애 치료 시장 규모 : 연령층별
- 40대 이상의 시장 규모
- 40대 이하의 시장 규모
・세계의 여성 성기능 장애 치료 시장 규모 : 제품별
- 비호르몬 요법의 시장 규모
- 호르몬 요법의 시장 규모
・고객 현황
・지역별 현황
- 북미의 여성 성기능 장애 치료 시장 규모
- 유럽의 여성 성기능 장애 치료 시장 규모
- 아시아의 여성 성기능 장애 치료 시장 규모
- 미국의 여성 성기능 장애 치료 시장 규모
- 캐나다의 여성 성기능 부전 치료 시장 규모
- 독일의 여성 성기능 장애 치료 시장 규모
- 영국의 여성 성기능 장애 치료 시장 규모
- 프랑스의 여성 성기능 장애 치료 시장 규모
- 기타 지역의 여성 성기능 장애 치료 시장 규모
・추진 요인/과제/동향
・기업 현황
・기업 분석
테크나비오사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 테크나비오사의 시장 조사 보고서는 정확한 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
■ 보고서 개요Global Female Sexual Dysfunction Treatment Market 2023-2027Technavio has been monitoring the female sexual dysfunction treatment market and it is poised to grow by $7760.77 mn during 2023-2027, accelerating at a CAGR of 34.28% during the forecast period. Our report on the female sexual dysfunction treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases, growing awareness of female sexual dysfunction, and approval and availability of drugs to treat hypoactive sexual desire disorder.
Technavio’s female sexual dysfunction treatment market is segmented as below:
By Age Group
• Above 40 years
• Below 40 years
By Product
• Non-hormonal therapy
• Hormonal therapy
By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the increasing R&D for the treatment of sexual dysfunction in women as one of the prime reasons driving the female sexual dysfunction treatment market growth during the next few years. Also, safety label changes for female sexual dysfunction therapy and increasing use of drugs causing sexual dysfunction in women will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the female sexual dysfunction treatment market covers the following areas:
• Female sexual dysfunction treatment market sizing
• Female sexual dysfunction treatment market forecast
• Female sexual dysfunction treatment market industry analysis
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female sexual dysfunction treatment market vendors that include Assos Ilac, Cipla Ltd., Dare Bioscience Inc., Dr Reddys Laboratories Ltd., Duchesnay Inc., Endo International Plc, Freya Pharma Solutions B.V., Lupin Ltd., Mithra Pharmaceuticals SA, Novo Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Pharmbio Korea Inc., Sprout Pharmaceuticals Inc., Strategic Science and Technologies LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the female sexual dysfunction treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
■ 보고서 목차• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Age Group
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global female sexual dysfunction treatment market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global female sexual dysfunction treatment market 2017 – 2021 ($ million)
o 4.2 Age Group Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Age Group Segment 2017 – 2021 ($ million)
o 4.3 Product Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Product Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Age Group
o 6.1 Market segments
o Exhibit 30: Chart on Age Group – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Age Group – Market share 2022-2027 (%)
o 6.2 Comparison by Age Group
o Exhibit 32: Chart on Comparison by Age Group
o Exhibit 33: Data Table on Comparison by Age Group
o 6.3 Above 40 years – Market size and forecast 2022-2027
o Exhibit 34: Chart on Above 40 years – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Above 40 years – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Above 40 years – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Above 40 years – Year-over-year growth 2022-2027 (%)
o 6.4 Below 40 years – Market size and forecast 2022-2027
o Exhibit 38: Chart on Below 40 years – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Below 40 years – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Below 40 years – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Below 40 years – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Age Group
o Exhibit 42: Market opportunity by Age Group ($ million)
• 7 Market Segmentation by Product
o 7.1 Market segments
o Exhibit 43: Chart on Product – Market share 2022-2027 (%)
o Exhibit 44: Data Table on Product – Market share 2022-2027 (%)
o 7.2 Comparison by Product
o Exhibit 45: Chart on Comparison by Product
o Exhibit 46: Data Table on Comparison by Product
o 7.3 Non-hormonal therapy – Market size and forecast 2022-2027
o Exhibit 47: Chart on Non-hormonal therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Data Table on Non-hormonal therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Chart on Non-hormonal therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 50: Data Table on Non-hormonal therapy – Year-over-year growth 2022-2027 (%)
o 7.4 Hormonal therapy – Market size and forecast 2022-2027
o Exhibit 51: Chart on Hormonal therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on Hormonal therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on Hormonal therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on Hormonal therapy – Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Product
o Exhibit 55: Market opportunity by Product ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 57: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 58: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 59: Chart on Geographic comparison
o Exhibit 60: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 61: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 63: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 64: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 65: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 67: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 68: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 69: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 73: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 77: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 81: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 85: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 UK – Market size and forecast 2022-2027
o Exhibit 89: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.11 France – Market size and forecast 2022-2027
o Exhibit 93: Chart on France – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on France – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on France – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on France – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 97: Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 98: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 99: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 100: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 101: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 102: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 103: Matrix on vendor position and classification
o 12.3 Cipla Ltd.
o Exhibit 104: Cipla Ltd. – Overview
o Exhibit 105: Cipla Ltd. – Business segments
o Exhibit 106: Cipla Ltd. – Key news
o Exhibit 107: Cipla Ltd. – Key offerings
o Exhibit 108: Cipla Ltd. – Segment focus
o 12.4 Dare Bioscience Inc.
o Exhibit 109: Dare Bioscience Inc. – Overview
o Exhibit 110: Dare Bioscience Inc. – Product / Service
o Exhibit 111: Dare Bioscience Inc. – Key offerings
o 12.5 Dr Reddys Laboratories Ltd.
o Exhibit 112: Dr Reddys Laboratories Ltd. – Overview
o Exhibit 113: Dr Reddys Laboratories Ltd. – Business segments
o Exhibit 114: Dr Reddys Laboratories Ltd. – Key offerings
o Exhibit 115: Dr Reddys Laboratories Ltd. – Segment focus
o 12.6 Duchesnay Inc.
o Exhibit 116: Duchesnay Inc. – Overview
o Exhibit 117: Duchesnay Inc. – Product / Service
o Exhibit 118: Duchesnay Inc. – Key offerings
o 12.7 Endo International Plc
o Exhibit 119: Endo International Plc – Overview
o Exhibit 120: Endo International Plc – Business segments
o Exhibit 121: Endo International Plc – Key news
o Exhibit 122: Endo International Plc – Key offerings
o Exhibit 123: Endo International Plc – Segment focus
o 12.8 Freya Pharma Solutions B.V.
o Exhibit 124: Freya Pharma Solutions B.V. – Overview
o Exhibit 125: Freya Pharma Solutions B.V. – Product / Service
o Exhibit 126: Freya Pharma Solutions B.V. – Key offerings
o 12.9 Lupin Ltd.
o Exhibit 127: Lupin Ltd. – Overview
o Exhibit 128: Lupin Ltd. – Product / Service
o Exhibit 129: Lupin Ltd. – Key news
o Exhibit 130: Lupin Ltd. – Key offerings
o 12.10 Mithra Pharmaceuticals SA
o Exhibit 131: Mithra Pharmaceuticals SA – Overview
o Exhibit 132: Mithra Pharmaceuticals SA – Product / Service
o Exhibit 133: Mithra Pharmaceuticals SA – Key offerings
o 12.11 Novo Nordisk AS
o Exhibit 134: Novo Nordisk AS – Overview
o Exhibit 135: Novo Nordisk AS – Business segments
o Exhibit 136: Novo Nordisk AS – Key offerings
o Exhibit 137: Novo Nordisk AS – Segment focus
o 12.12 Palatin Technologies Inc.
o Exhibit 138: Palatin Technologies Inc. – Overview
o Exhibit 139: Palatin Technologies Inc. – Product / Service
o Exhibit 140: Palatin Technologies Inc. – Key offerings
o 12.13 Pfizer Inc.
o Exhibit 141: Pfizer Inc. – Overview
o Exhibit 142: Pfizer Inc. – Product / Service
o Exhibit 143: Pfizer Inc. – Key news
o Exhibit 144: Pfizer Inc. – Key offerings
o 12.14 Sprout Pharmaceuticals Inc.
o Exhibit 145: Sprout Pharmaceuticals Inc. – Overview
o Exhibit 146: Sprout Pharmaceuticals Inc. – Product / Service
o Exhibit 147: Sprout Pharmaceuticals Inc. – Key offerings
o 12.15 Strategic Science and Technologies LLC
o Exhibit 148: Strategic Science and Technologies LLC – Overview
o Exhibit 149: Strategic Science and Technologies LLC – Product / Service
o Exhibit 150: Strategic Science and Technologies LLC – Key offerings
o 12.16 Teva Pharmaceutical Industries Ltd.
o Exhibit 151: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 152: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 153: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 154: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 155: Teva Pharmaceutical Industries Ltd. – Segment focus
o 12.17 Viatris Inc.
o Exhibit 156: Viatris Inc. – Overview
o Exhibit 157: Viatris Inc. – Business segments
o Exhibit 158: Viatris Inc. – Key offerings
o Exhibit 159: Viatris Inc. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 160: Inclusions checklist
o Exhibit 161: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 162: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 163: Research methodology
o Exhibit 164: Validation techniques employed for market sizing
o Exhibit 165: Information sources
o 13.5 List of abbreviations
o Exhibit 166: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Age Group
Exhibits6: Executive Summary – Chart on Market Segmentation by Product
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global female sexual dysfunction treatment market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Age Group Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Product Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Age Group – Market share 2022-2027 (%)
Exhibits31: Data Table on Age Group – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Age Group
Exhibits33: Data Table on Comparison by Age Group
Exhibits34: Chart on Above 40 years – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Above 40 years – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Above 40 years – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Above 40 years – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Below 40 years – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Below 40 years – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Below 40 years – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Below 40 years – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Age Group ($ million)
Exhibits43: Chart on Product – Market share 2022-2027 (%)
Exhibits44: Data Table on Product – Market share 2022-2027 (%)
Exhibits45: Chart on Comparison by Product
Exhibits46: Data Table on Comparison by Product
Exhibits47: Chart on Non-hormonal therapy – Market size and forecast 2022-2027 ($ million)
Exhibits48: Data Table on Non-hormonal therapy – Market size and forecast 2022-2027 ($ million)
Exhibits49: Chart on Non-hormonal therapy – Year-over-year growth 2022-2027 (%)
Exhibits50: Data Table on Non-hormonal therapy – Year-over-year growth 2022-2027 (%)
Exhibits51: Chart on Hormonal therapy – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on Hormonal therapy – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on Hormonal therapy – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on Hormonal therapy – Year-over-year growth 2022-2027 (%)
Exhibits55: Market opportunity by Product ($ million)
Exhibits56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits57: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits58: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits59: Chart on Geographic comparison
Exhibits60: Data Table on Geographic comparison
Exhibits61: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits62: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits63: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits64: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits65: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits66: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits67: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits68: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits69: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on France – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on France – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on France – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on France – Year-over-year growth 2022-2027 (%)
Exhibits97: Market opportunity By Geographical Landscape ($ million)
Exhibits98: Impact of drivers and challenges in 2022 and 2027
Exhibits99: Overview on Criticality of inputs and Factors of differentiation
Exhibits100: Overview on factors of disruption
Exhibits101: Impact of key risks on business
Exhibits102: Vendors covered
Exhibits103: Matrix on vendor position and classification
Exhibits104: Cipla Ltd. – Overview
Exhibits105: Cipla Ltd. – Business segments
Exhibits106: Cipla Ltd. – Key news
Exhibits107: Cipla Ltd. – Key offerings
Exhibits108: Cipla Ltd. – Segment focus
Exhibits109: Dare Bioscience Inc. – Overview
Exhibits110: Dare Bioscience Inc. – Product / Service
Exhibits111: Dare Bioscience Inc. – Key offerings
Exhibits112: Dr Reddys Laboratories Ltd. – Overview
Exhibits113: Dr Reddys Laboratories Ltd. – Business segments
Exhibits114: Dr Reddys Laboratories Ltd. – Key offerings
Exhibits115: Dr Reddys Laboratories Ltd. – Segment focus
Exhibits116: Duchesnay Inc. – Overview
Exhibits117: Duchesnay Inc. – Product / Service
Exhibits118: Duchesnay Inc. – Key offerings
Exhibits119: Endo International Plc – Overview
Exhibits120: Endo International Plc – Business segments
Exhibits121: Endo International Plc – Key news
Exhibits122: Endo International Plc – Key offerings
Exhibits123: Endo International Plc – Segment focus
Exhibits124: Freya Pharma Solutions B.V. – Overview
Exhibits125: Freya Pharma Solutions B.V. – Product / Service
Exhibits126: Freya Pharma Solutions B.V. – Key offerings
Exhibits127: Lupin Ltd. – Overview
Exhibits128: Lupin Ltd. – Product / Service
Exhibits129: Lupin Ltd. – Key news
Exhibits130: Lupin Ltd. – Key offerings
Exhibits131: Mithra Pharmaceuticals SA – Overview
Exhibits132: Mithra Pharmaceuticals SA – Product / Service
Exhibits133: Mithra Pharmaceuticals SA – Key offerings
Exhibits134: Novo Nordisk AS – Overview
Exhibits135: Novo Nordisk AS – Business segments
Exhibits136: Novo Nordisk AS – Key offerings
Exhibits137: Novo Nordisk AS – Segment focus
Exhibits138: Palatin Technologies Inc. – Overview
Exhibits139: Palatin Technologies Inc. – Product / Service
Exhibits140: Palatin Technologies Inc. – Key offerings
Exhibits141: Pfizer Inc. – Overview
Exhibits142: Pfizer Inc. – Product / Service
Exhibits143: Pfizer Inc. – Key news
Exhibits144: Pfizer Inc. – Key offerings
Exhibits145: Sprout Pharmaceuticals Inc. – Overview
Exhibits146: Sprout Pharmaceuticals Inc. – Product / Service
Exhibits147: Sprout Pharmaceuticals Inc. – Key offerings
Exhibits148: Strategic Science and Technologies LLC – Overview
Exhibits149: Strategic Science and Technologies LLC – Product / Service
Exhibits150: Strategic Science and Technologies LLC – Key offerings
Exhibits151: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits152: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits153: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits154: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits155: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits156: Viatris Inc. – Overview
Exhibits157: Viatris Inc. – Business segments
Exhibits158: Viatris Inc. – Key offerings
Exhibits159: Viatris Inc. – Segment focus
Exhibits160: Inclusions checklist
Exhibits161: Exclusions checklist
Exhibits162: Currency conversion rates for US$
Exhibits163: Research methodology
Exhibits164: Validation techniques employed for market sizing
Exhibits165: Information sources
Exhibits166: List of abbreviations
|
| ※본 조사보고서 [세계의 여성 성기능 장애 치료 시장 (2023년~2027년)] (코드 : IRTNTR70409-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 여성 성기능 장애 치료 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
